Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Immunotherapy Drugs Market

Immunotherapy Drugs Market Share

Report ID: GMI9713
Published Date: May 2024
Report Format: PDF

Download Free Sample

Immunotherapy Drugs Market Share

The market has surged due to rising cancer rates globally, advancements in biotechnology, and supportive regulatory policies. Immunotherapy offers targeted treatments, often with fewer side effects compared to conventional therapies, driving its adoption. Major pharmaceutical companies are heavily investing in R&D, expanding the range of immunotherapy drugs available, including immune checkpoint inhibitors, monoclonal antibodies, and CAR-T cell therapies. Combining therapies, personalized medicine, and exploring new indications further boost market growth. With ongoing innovation and collaboration, immunotherapy is poised to revolutionize cancer care and extend its impact to other medical fields.

Immunotherapy Drugs Market Companies

Prominent players operating in the immunotherapy drugs industry include:

AbbVie Inc.
Amgen Inc.
AstraZeneca
Bayer AG
Boehringer Ingelheim
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genmab A/S
GSK plc
Immatics N.V.
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
Sanofi

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The immunotherapy drugs market was valued at USD 182.5 billion in 2023 and is expected to exhibit growth at 10.4% CAGR from 2024

The monoclonal antibodies segment of the market generated USD 96.6 billion in 2023 and will grow rapidly through 2032, as they offer potent and durable therapeutic effects, often achieving higher efficacy rates.

North America immunotherapy drugs market size was USD 70.3 billion in 2023 and is anticipated to grow at 10.2% CAGR between 2024

AbbVie Inc, Amgen Inc, AstraZeneca, Bayer AG, Boehringer Ingelheim, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and Genmab A/S, GSK plc among others.